Skip to main content
For CROs and Biobanks

Get scale at your fingertips

Whether you’re identifying sites and patients for a sponsor or sourcing hard-to-find biospecimens, OncoLens gives CROs and biobank teams the same community-weighted reach, and the data behind it.

Faster, more precise delivery See network coverage
One research network of 225+ cancer centers feeds OncoLens feasibility matching to your request, powered by AI extraction. For CROs, sites and PIs are selected, then pre-screening. For biobanks, sites are selected, then specimens and de-identified data are collected.

How OncoLens helps

Two audiences, one network.

For CROs

OncoLens identifies trial-ready sites and pre-screens patients

  • OncoLens covers 225+ sites, 90% community-based, Phase 1 to Phase 3 compatible
  • Feasibility-based connections and introductions go directly to centers and PIs
  • Paired with oncology-focused AI pre-screening
  • Turnkey dashboards, personalized alerts, and analytics on eligibility and declines come back to you
For biobanks

OncoLens sources hard-to-find oncology biospecimens with context

  • OncoLens fulfills hard-to-source biospecimen needs through the same research network
  • Collections are enriched with underlying de-identified patient data
  • None of it exposes patient identity

What you receive

Two deliverables out of one network, each with the data behind it.

FOR CROs

Feasibility results

1 2 3 4
  1. 1Sites and PIs matched to your protocol
  2. 2Feasibility-based introductions
  3. 3Pre-screened patient matches
  4. 4Eligibility and decline analytics
FOR BIOBANKS

Specimen manifest

1 2 3 4
  1. 1Hard-to-source biospecimens
  2. 2De-identified patient data
  3. 3Diagnosis and treatment history
  4. 4Sourced across the same network
88%

88% of actionable clinical data points came from unstructured sources: narrative notes, pathology reports and radiology impressions. OncoLens AI extracts it, so it’s part of every match and every manifest you receive.

Source: OncoLens Analytics case study, 2026

County-level map showing where patients under care in the OncoLens network are concentrated across the United States, with Alaska and Hawaii shown as insets
Where patients under care are concentrated
225+U.S.-based cancer center locations
6,000,000+patients under care
90%community-based
88%AI-extracted insights

Frequently asked questions

How does OncoLens help CROs identify oncology trial sites faster?

OncoLens connects CROs and sponsors to the OncoLens Research Network, spanning 225+ cancer center locations with roughly 90% community-based reach, supporting Phase 1 through Phase 3 studies. Teams get feasibility-based connections and introductions to the centers and PIs most likely to fit a given protocol, shortening the path from site identification to activation.

What does “feasibility-based” site selection mean at OncoLens?

Rather than surfacing a generic directory of investigator sites, OncoLens matches centers and PIs based on demonstrated fit for a specific protocol and patient population, then facilitates the introduction directly, so outreach time goes toward sites with a real chance of enrolling.

How does OncoLens’s AI patient pre-screening work?

OncoLens’s oncology-focused AI reviews patient data against trial eligibility criteria and presents likely candidates through turnkey dashboards, with personalized alerts as new matches emerge. A human is always in the loop to confirm eligibility, and teams get analytics on eligibility and decline trends.

Can OncoLens help translational medicine and biobank teams source hard-to-find biospecimens?

Yes. The OncoLens Research Network‘s reach across 225+ cancer center locations, most of them community-based, gives biobank teams a path to specimen types that are difficult to source through a single institution or a narrow academic network.

What data comes with biospecimens sourced through OncoLens?

Biospecimens sourced through the OncoLens Research Network can be paired with de-identified patient data from that same network, giving translational teams clinical context, such as diagnosis and treatment history, behind each sample, without exposing patient identity.

Explore other audiences

OncoLens supports teams across the life sciences organization.

Audience

RWE and HEOR

Data captured at the point of clinical decision-making, not just claims.

 Audience

Commercial

Unparalleled reach across outpatient and inpatient oncology care.

 Audience

Clinical Development

Reduce uncertainty from feasibility through enrollment.

 Audience

Market Access and Data Insights

Where real-world care diverges from guidelines.
Get in touch

Scale your next sponsor engagement or specimen request

Share what you’re sourcing, whether sites, patients, or specimens, and OncoLens will show you what the network already has.